Symbols / IMMP
IMMP Chart
About
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 410.67M |
| Enterprise Value | 3.98B | Income | -61.43M | Sales | 5.04M |
| Book/sh | 0.07 | Cash/sh | 0.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -11.39 | PEG | — |
| P/S | 81.42 | P/B | 40.32 | P/C | — |
| EV/EBITDA | -63.33 | EV/Sales | 789.48 | Quick Ratio | 11.02 |
| Current Ratio | 11.69 | Debt/Eq | 1.13 | LT Debt/Eq | — |
| EPS (ttm) | -0.42 | EPS next Y | -0.24 | EPS Growth | — |
| Revenue Growth | 9.50% | Earnings | 2026-02-26 | ROA | -22.66% |
| ROE | -36.88% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -20.35% | Profit Margin | 0.00% | Shs Outstand | 147.19M |
| Shs Float | 1.22B | Short Float | 3.24% | Short Ratio | 23.77 |
| Short Interest | — | 52W High | 3.53 | 52W Low | 1.32 |
| Beta | 1.69 | Avg Volume | 739.72K | Volume | 45.03K |
| Target Price | $9.50 | Recom | None | Prev Close | $2.80 |
| Price | $2.79 | Change | -0.36% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$2.80
Latest analyst target
3. DCF / Fair value
$-5.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.80
Low
$7.00
High
$12.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | init | Citizens | — → Market Outperform | $10 |
| 2026-02-17 | init | Citizens | — → Market Outperform | $6 |
| 2024-11-15 | main | Baird | Outperform → Outperform | $7 |
| 2024-06-27 | main | Baird | Outperform → Outperform | $6 |
| 2024-05-17 | init | Capital One | — → Overweight | $10 |
| 2023-08-28 | reit | Baird | Outperform → Outperform | $7 |
| 2023-08-03 | init | Baird | — → Outperform | $7 |
| 2023-08-03 | init | Baird | — → Outperform | $7 |
| 2023-05-18 | main | Maxim Group | Buy → Buy | $10 |
| 2021-08-03 | init | Ladenburg Thalmann | — → Buy | $8 |
| 2018-05-29 | main | Maxim Group | Buy → Buy | $7 |
- Immutep (IMMP) Receives Updated Analyst Coverage with New Price - GuruFocus Mon, 23 Feb 2026 15
- Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm - Yahoo Finance Mon, 15 Dec 2025 08
- Global lung cancer trial tests efti + KEYTRUDA combo as potential new standard - Stock Titan Fri, 06 Feb 2026 08
- Immutep Limited (IMMP) Stock Analysis: Exploring a 251.85% Potential Upside in Biotech Breakthroughs - DirectorsTalk Interviews hu, 05 Feb 2026 08
- Immutep Limited: Surging On Positive Head And Neck Data (NASDAQ:IMMP) - Seeking Alpha hu, 08 May 2025 07
- IMMP: Immutep Coverage Initiated with Market Outperform Rating | - GuruFocus ue, 17 Feb 2026 15
- Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Yahoo Finance Wed, 10 Dec 2025 08
- Immutep Limited (IMMP) Stock Analysis: Exploring a Potential 375% Upside in the Biotech Sector - DirectorsTalk Interviews hu, 23 Oct 2025 07
- Experimental antibody in early trial dampens T cells driving autoimmune disease - Stock Titan Mon, 22 Dec 2025 08
- Is IMMP subject to activist investor interest - July 2025 Earnings & Detailed Earnings Play Alerts - mfd.ru Sun, 08 Feb 2026 15
- Hot Stocks: Immutep, DroneShield, Venari Minerals - Sharecafe ue, 16 Dec 2025 08
- 7 Best ASX Stocks to Buy Right Now - Insider Monkey Sun, 14 Dec 2025 08
- Immutep Limited (IMMP) Stock Analysis: Exploring a Remarkable 382% Potential Upside in the Biotech Sector - DirectorsTalk Interviews hu, 30 Oct 2025 07
- Immutep (NASDAQ: IMMP) lands efti licensing deal and funds runway to Q2 2027 - Stock Titan hu, 29 Jan 2026 08
- Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Yahoo Finance Sun, 29 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 545.76K | -2.75M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.30 | 0.30 |
| NormalizedEBITDA | -42.80M | -40.63M | -33.94M | -20.72M |
| TotalUnusualItems | 113.46K | 755.41K | 1.82M | -9.17M |
| TotalUnusualItemsExcludingGoodwill | 113.46K | 755.41K | 1.82M | -9.17M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -42.72M | -39.90M | -32.21M | -29.90M |
| ReconciledDepreciation | 3.00M | |||
| EBITDA | -42.69M | -39.88M | -32.12M | -29.89M |
| EBIT | -42.69M | -39.88M | -32.12M | -29.89M |
| NetInterestIncome | 3.85M | 918.60K | 132.09K | 95.50K |
| InterestExpense | 30.59K | 20.40K | 92.43K | 9.82K |
| InterestIncome | 3.88M | 939.00K | 224.52K | 105.33K |
| NormalizedIncome | -42.83M | -40.65M | -33.48M | -23.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -42.72M | -39.90M | -32.21M | -29.90M |
| TotalExpenses | 46.56M | 41.43M | 34.01M | 19.66M |
| DilutedAverageShares | 145.58M | 120.11M | 89.24M | 87.03M |
| BasicAverageShares | 145.58M | 120.11M | 89.24M | 87.03M |
| DilutedEPS | -0.42 | -0.36 | -0.45 | -0.37 |
| BasicEPS | -0.42 | -0.36 | -0.45 | -0.37 |
| DilutedNIAvailtoComStockholders | -42.72M | -39.90M | -32.21M | -29.90M |
| NetIncomeCommonStockholders | -42.72M | -39.90M | -32.21M | -29.90M |
| NetIncome | -42.72M | -39.90M | -32.21M | -29.90M |
| NetIncomeIncludingNoncontrollingInterests | -42.72M | -39.90M | -32.21M | -29.90M |
| NetIncomeContinuousOperations | -42.72M | -39.90M | -32.21M | -29.90M |
| TaxProvision | 0.00 | 0.00 | 34.00 | 33.00 |
| PretaxIncome | -42.72M | -39.90M | -32.21M | -29.90M |
| OtherIncomeExpense | -11.33K | 616.36K | 1.49M | -10.34M |
| OtherNonOperatingIncomeExpenses | -124.78K | -139.05K | -324.74K | -1.17M |
| GainOnSaleOfSecurity | 113.46K | 755.41K | 1.82M | -9.17M |
| NetNonOperatingInterestIncomeExpense | 3.85M | 918.60K | 132.09K | 95.50K |
| InterestExpenseNonOperating | 30.59K | 20.40K | 92.43K | 9.82K |
| InterestIncomeNonOperating | 3.88M | 939.00K | 224.52K | 105.33K |
| OperatingIncome | -46.56M | -41.43M | -33.84M | -19.66M |
| OperatingExpense | 46.56M | 41.43M | 34.01M | 19.66M |
| OtherOperatingExpenses | -3.84M | -3.51M | -4.54M | -3.86M |
| ResearchAndDevelopment | 41.55M | 36.26M | 31.34M | 17.24M |
| SellingGeneralAndAdministration | 8.85M | 8.68M | 7.21M | 6.28M |
| GeneralAndAdministrativeExpense | 8.85M | 8.68M | 7.21M | 6.28M |
| OtherGandA | 8.85M | 8.68M | 7.21M | 6.28M |
| TotalRevenue | 0.00 | 0.00 | 170.37K | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 170.37K | 0.00 |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.45B | 1.20B | 888.01M | 766.95M |
| ShareIssued | 1.45B | 1.20B | 888.01M | 766.95M |
| TotalDebt | 1.59M | 1.23M | 1.73M | 2.82M |
| TangibleBookValue | 181.28M | 126.98M | 83.52M | 60.42M |
| InvestedCapital | 190.48M | 137.30M | 95.53M | 75.80M |
| WorkingCapital | 180.86M | 125.19M | 84.40M | 63.08M |
| NetTangibleAssets | 181.28M | 126.98M | 83.52M | 60.42M |
| CapitalLeaseObligations | 633.03K | 392.82K | 280.87K | 288.31K |
| CommonStockEquity | 189.52M | 136.47M | 94.08M | 73.27M |
| TotalCapitalization | 190.48M | 137.30M | 95.53M | 75.80M |
| TotalEquityGrossMinorityInterest | 189.52M | 136.47M | 94.08M | 73.27M |
| StockholdersEquity | 189.52M | 136.47M | 94.08M | 73.27M |
| GainsLossesNotAffectingRetainedEarnings | 30.06M | 30.13M | 29.00M | 34.49M |
| RetainedEarnings | -382.65M | -339.93M | -302.34M | -274.64M |
| CapitalStock | 542.11M | 446.27M | 367.41M | 313.42M |
| CommonStock | 542.11M | 446.27M | 367.41M | 313.42M |
| TotalLiabilitiesNetMinorityInterest | 12.06M | 10.98M | 8.09M | 8.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.57M | 1.21M | 1.68M | 3.42M |
| DerivativeProductLiabilities | 0.00 | 0.00 | 722.97K | |
| EmployeeBenefits | 203.18K | 164.43K | 117.25K | 88.92K |
| NonCurrentDeferredLiabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 1.36M | 1.04M | 1.56M | 2.61M |
| LongTermCapitalLeaseObligation | 399.41K | 207.62K | 107.49K | 80.11K |
| LongTermDebt | 960.76K | 835.45K | 1.45M | 2.53M |
| LongTermProvisions | 7.84K | |||
| CurrentLiabilities | 10.49M | 9.77M | 6.41M | 5.34M |
| OtherCurrentLiabilities | 131.90K | |||
| CurrentDebtAndCapitalLeaseObligation | 233.62K | 185.21K | 173.38K | 208.19K |
| CurrentCapitalLeaseObligation | 233.62K | 185.21K | 173.38K | 208.19K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 690.57K | 562.30K | 357.03K | 350.13K |
| PayablesAndAccruedExpenses | 9.56M | 9.02M | 5.75M | 4.78M |
| CurrentAccruedExpenses | 5.34M | 3.22M | ||
| Payables | 4.22M | 5.80M | 5.75M | 4.78M |
| OtherPayable | 428.71K | 354.84K | 2.89M | 2.96M |
| AccountsPayable | 3.79M | 5.45M | 2.87M | 1.82M |
| TotalAssets | 201.58M | 147.45M | 102.17M | 82.03M |
| TotalNonCurrentAssets | 10.23M | 12.48M | 11.36M | 13.61M |
| NonCurrentPrepaidAssets | 1.31M | 2.52M | 495.66K | 454.19K |
| GoodwillAndOtherIntangibleAssets | 8.24M | 9.49M | 10.55M | 12.85M |
| OtherIntangibleAssets | 8.13M | 9.38M | 10.44M | 12.74M |
| Goodwill | 109.96K | 109.96K | 109.96K | 109.96K |
| NetPPE | 679.72K | 468.51K | 308.08K | 309.70K |
| AccumulatedDepreciation | -692.01K | -644.71K | -632.99K | -629.61K |
| GrossPPE | 1.37M | 1.11M | 941.07K | 939.31K |
| MachineryFurnitureEquipment | 755.16K | 727.85K | 670.93K | 670.50K |
| BuildingsAndImprovements | 616.58K | 385.37K | 270.15K | 268.81K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 191.35M | 134.97M | 90.81M | 68.42M |
| RestrictedCash | 0.00 | 0.00 | 0.00 | 465.00K |
| PrepaidAssets | 1.92M | 3.57M | 2.44M | 1.70M |
| Receivables | 7.56M | 7.97M | 8.37M | 6.12M |
| OtherReceivables | 6.30M | 6.06M | 6.27M | 5.30M |
| TaxesReceivable | 1.25M | 1.78M | 2.09M | 775.40K |
| AccruedInterestReceivable | 21.07K | 43.00 | 179.00 | |
| AccountsReceivable | 5.24K | 130.68K | 17.36K | 51.31K |
| CashCashEquivalentsAndShortTermInvestments | 181.88M | 123.42M | 80.00M | 60.13M |
| OtherShortTermInvestments | 20.09M | 0.00 | ||
| CashAndCashEquivalents | 161.79M | 123.42M | 80.00M | 60.13M |
| CashEquivalents | 66.86M | 3.59M | 302.00K | 8.28M |
| CashFinancial | 94.93M | 119.83M | 79.69M | 51.85M |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -35.75M | -35.44M | -30.25M | -17.66M |
| RepaymentOfDebt | -226.49K | -211.97K | -222.54K | -214.38K |
| IssuanceOfCapitalStock | 100.24M | 80.08M | 52.98M | 43.31M |
| CapitalExpenditure | -932.37K | -82.73K | -22.91K | -15.60K |
| EndCashPosition | 161.79M | 123.42M | 80.00M | 60.59M |
| BeginningCashPosition | 123.42M | 80.00M | 60.59M | 26.32M |
| EffectOfExchangeRateChanges | -967.73K | 2.84M | -671.03K | -752.84K |
| ChangesInCash | 39.34M | 40.58M | 20.07M | 35.02M |
| FinancingCashFlow | 95.18M | 76.02M | 50.33M | 52.68M |
| CashFlowFromContinuingFinancingActivities | 95.18M | 76.02M | 50.33M | 52.68M |
| NetOtherFinancingCharges | -4.83M | -3.85M | -2.43M | -1.68M |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 11.27M | |
| NetCommonStockIssuance | 100.24M | 80.08M | 52.98M | 43.31M |
| CommonStockIssuance | 100.24M | 80.08M | 52.98M | 43.31M |
| NetIssuancePaymentsOfDebt | -226.49K | -211.97K | -222.54K | -214.38K |
| NetLongTermDebtIssuance | -226.49K | -211.97K | -222.54K | -214.38K |
| LongTermDebtPayments | -226.49K | -211.97K | -222.54K | -214.38K |
| InvestingCashFlow | -21.02M | -82.73K | -22.91K | -15.60K |
| CashFlowFromContinuingInvestingActivities | -21.02M | -82.73K | -22.91K | -15.60K |
| NetInvestmentPurchaseAndSale | -20.09M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -20.09M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -903.15K | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -903.15K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -29.21K | -82.73K | -22.91K | -15.60K |
| PurchaseOfPPE | -29.21K | -82.73K | -22.91K | -15.60K |
| OperatingCashFlow | -43.94M | |||
| CashFlowFromContinuingOperatingActivities | -43.94M | |||
| ChangeInWorkingCapital | -2.27M | |||
| ChangeInOtherWorkingCapital | 51.21K | |||
| ChangeInOtherCurrentAssets | -1.14M | |||
| ChangeInPayablesAndAccruedExpense | 2.09M | |||
| ChangeInPayable | 2.09M | |||
| ChangeInReceivables | -3.27M | |||
| OtherNonCashItems | 472.06K | |||
| StockBasedCompensation | 2.16M | |||
| DepreciationAmortizationDepletion | 3.00M | |||
| DepreciationAndAmortization | 3.00M | |||
| OperatingGainsLosses | -483.75K | |||
| GainLossOnInvestmentSecurities | -859.23K | |||
| NetForeignCurrencyExchangeGainLoss | 375.48K | |||
| NetIncomeFromContinuingOperations | -46.82M | |||
| CashFlowsfromusedinOperatingActivitiesDirect | -34.82M | -35.36M | -30.23M | -17.64M |
| TaxesRefundPaidDirect | 0.00 | 0.00 | -34.00 | -33.00 |
| InterestReceivedDirect | 3.70M | 918.00K | 224.66K | 112.24K |
| InterestPaidDirect | -30.01K | -20.54K | -92.43K | -13.15K |
| ClassesofCashPayments | -42.45M | -39.99M | -33.84M | -19.51M |
| PaymentstoSuppliersforGoodsandServices | -42.45M | -39.99M | -33.84M | -19.51M |
| ClassesofCashReceiptsfromOperatingActivities | 3.96M | 3.74M | 3.48M | 1.77M |
| OtherCashReceiptsfromOperatingActivities | 199.25K | 82.32K | 86.99K | 322.59K |
| ReceiptsfromGovernmentGrants | 3.76M | 3.66M | 3.30M | 1.31M |
| ReceiptsfromCustomers | 0.00 | 0.00 | 87.82K | 138.31K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IMMP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|